Damora Therapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Damora Therapeutics, Inc. (DMRA), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are DMRA insiders buying or selling?
In the last 12 months, Damora Therapeutics, Inc. insiders reported 1 open-market purchase ($252.9K) and 4 sales ($30.7K) — net buying of $222.2K. Since November 2020, Trabud has recorded 32 Form 4 filings for DMRA: 16 buys ($28.4M) and 16 sells ($2.2M).
Source: SEC EDGAR Form 4
Key Statistics (November 2020 – Sep 28, 2026)
Total Form 4 filings
32
SEC EDGAR
Insider filers
10
Insider buys (16)
$28.4M
Insider sells (16)
$2.2M
Insider sentiment
Net buyingNet insider flow of $26.2M in net buying since November 2020, and $222.2K in net buying over the last 12 months. 1 insider buy in the last 90 days.
Recent DMRA insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 28, 2026 | Jennifer Jarrett | Director, President and CEO | Purchase | 12.5K | $20.23 | $252.9K | SEC ↗ |
| Jul 8, 2026 | Garrett Winslow | General Counsel | Sale | 245 | $29.98 | $7.3K | SEC ↗ |
| Jan 6, 2026 | Hans T. Schambye | Chief Executive Officer | Sale | 700 | $21.38 | $15.0K | SEC ↗ |
| Jan 6, 2026 | Garrett Winslow | General Counsel | Sale | 255 | $21.38 | $5.5K | SEC ↗ |
| Jan 6, 2026 | Lori Firmani | Chief Financial Officer | Sale | 135 | $21.41 | $2.9K | SEC ↗ |
| Jul 8, 2025 | Hans T. Schambye | Chief Executive Officer | Sale | 735 | $3.38 | $2.5K | SEC ↗ |
| Jul 8, 2025 | Garrett Winslow | General Counsel | Sale | 260 | $3.39 | $881.4 | SEC ↗ |
| Jul 8, 2025 | Lori Firmani | Interim CFO | Sale | 147 | $3.39 | $498.33 | SEC ↗ |
| Jan 7, 2025 | Garrett Winslow | General Counsel | Sale | 471 | $5.60 | $2.6K | SEC ↗ |
| Jan 7, 2025 | Lori Firmani | Interim CFO | Sale | 261 | $5.63 | $1.5K | SEC ↗ |
| Jan 7, 2025 | Hans T. Schambye | Chief Executive Officer | Sale | 1.3K | $5.60 | $7.5K | SEC ↗ |
| Aug 17, 2023 | ORBIMED ADVISORS LLC | 10% Owner | Sale | 822.7K | $0.75 | $617.0K | SEC ↗ |
| Aug 2, 2023 | ORBIMED ADVISORS LLC | 10% Owner | Sale | 209.4K | $3.00 | $628.2K | SEC ↗ |
| Jul 17, 2023 | ORBIMED ADVISORS LLC | 10% Owner | Sale | 194.7K | $2.40 | $467.3K | SEC ↗ |
| Apr 17, 2023 | ORBIMED ADVISORS LLC | 10% Owner | Sale | 68.5K | $1.87 | $128.3K | SEC ↗ |
| Apr 12, 2023 | ORBIMED ADVISORS LLC | 10% Owner | Sale | 67.5K | $1.80 | $121.4K | SEC ↗ |
| Apr 7, 2023 | ORBIMED ADVISORS LLC | 10% Owner | Sale | 102.6K | $2.16 | $222.0K | SEC ↗ |
| Mar 23, 2022 | Bertil Lindmark | Chief Medical Officer | Purchase | 14.6K | $2.16 | $31.5K | SEC ↗ |
| Mar 23, 2022 | Hans T. Schambye | Chief Executive Officer | Purchase | 5.0K | $2.15 | $10.8K | SEC ↗ |
| Dec 6, 2021 | Garrett Winslow | General Counsel | Purchase | 2.0K | $2.48 | $5.0K | SEC ↗ |
| Dec 6, 2021 | Jonathan Freve | Chief Financial Officer | Purchase | 4.0K | $2.49 | $10.0K | SEC ↗ |
| Nov 10, 2021 | Hans T. Schambye | Chief Executive Officer | Purchase | 4.5K | $3.50 | $15.8K | SEC ↗ |
| Nov 9, 2021 | Jonathan Freve | Chief Financial Officer | Purchase | 3.0K | $3.40 | $10.2K | SEC ↗ |
| Aug 19, 2021 | Jonathan Freve | Chief Financial Officer | Purchase | 3.0K | $3.92 | $11.8K | SEC ↗ |
| Jun 28, 2021 | Bertil Lindmark | Chief Medical Officer | Purchase | 2.0K | $5.26 | $10.5K | SEC ↗ |
Showing the 25 most recent of 32 Form 4 filings for Damora Therapeutics, Inc..
Most active DMRA insiders
- ORBIMED ADVISORS LLC7 filings
- Garrett Winslow6 filings
- Hans T. Schambye6 filings
- Jonathan Freve4 filings
- Lori Firmani3 filings
Ask anything about DMRA insider activity
Use Trabud's AI agent to query Damora Therapeutics, Inc.'s Form 4 history in plain English — "Show me DMRA CEO purchases this year" or compare it against any other ticker.
Open the AI agentDMRA insider trading FAQ
Are Damora Therapeutics, Inc. insiders buying or selling?
In the last 12 months, Damora Therapeutics, Inc. insiders reported 1 open-market purchase ($252.9K) and 4 sales ($30.7K) — net buying of $222.2K. Since November 2020, Trabud has recorded 32 Form 4 filings for DMRA: 16 buys ($28.4M) and 16 sells ($2.2M). Over the full record that is net buying of $26.2M.
How many insiders trade DMRA stock?
10 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Damora Therapeutics, Inc.. The most recent filing was accepted on Sep 28, 2026.
Where does Trabud get DMRA insider trading data?
All DMRA insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.